COVID-19 Information

We're here to keep you informed, and care for your health. MultiCare facilities are open for all patients. COVID-19 Resource Center


Carol Wysham, MD

Carol  Wysham, MD

Carol Wysham, MD

Endocrinology, Endo, Diabetes & Metabolism

Accepting New Patients

Phone: 509-342-3450    Fax: 509-459-1595

Call For an Appointment

Provider Details

Certification: American Board of Internal Medicine; Endocrinology and Metabolism Subspecialty, American Board of Internal Medicine

Medical Association Memberships: Endocrine Society Fellow, American College of Physicians Fellow, American College of Endocrinology American Diabetes Association

Professional School: University of Iowa College of Medicine, Iowa City, IA

Residency: Internal Medicine, Oregon Health Sciences University, Portland, OR

Fellowship: Endocrinology and Metabolism, University of Iowa Hospitals & Clinics, Iowa City, IA

Special Interests: Diabetes, General Endocrinology

Research & Publications

Wysham CH, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Duh MS, Young JB. Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study. Curr Med Res Opin. 2020 Feb;36(2):219-227. doi: 10.1080/03007995.2019.1682981.

Freemantle N, Mauricio D, Giaccari A, Bailey T, Roussel R, Franco D, Berthou B, Pilorget V, Westerbacka J, Bosnyak Z, Bonnemaire M, Cali AMG, Nguyên-Pascal ML, Penfornis A, Perez-Maraver M, Seufert J, Sullivan SD, Wilding J, Wysham C, Davies M. Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. Curr Med Res Opin. 2020 Jan 19:1-11. doi: 10.1080/03007995.2019.1708287. 

Tabák ÁG, Anderson J, Aschner P, Liu M, Saremi A, Stella P, Tinahones FJ, Wysham C, Meier JJ. Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis. Diabetes Ther. 2020 Jan;11(1):305-318. doi: 10.1007/s13300-019-00735-7. 

Kuritzky L, Reid TS, Wysham CH. Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers. Clin Diabetes. 2019 Oct;37(4):368-376. doi: 10.2337/cd18-0091.

Heller SR, DeVries JH, Wysham C, Hansen CT, Hansen MV, Frier BM. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2. Diabetes Obes Metab. 2019 Jul;21(7):1634-1641. doi: 10.1111/dom.13708. Epub 2019 Apr 15.

Neumiller JJ, Kalyani RR, Herman WH, Grant RW, Wysham CH, Inzucchi SE, Hirsch IB, Fonseca VA, Buse JB, Barrett EJ. Evidence supports prediabetes treatment. Science. 2019 Apr 26;364(6438):341-342. doi: 10.1126/science.aax3548.

DeVries JH, Bailey TS, Bhargava A, Gerety G, Gumprecht J, Heller S, Lane W, Wysham CH, Zinman B, Bak BA, Hachmann-Nielsen E, Philis-Tsimikas A. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials. Diabetes Obes Metab. 2019 Mar;21(3):622-630. doi: 10.1111/dom.13565. Epub 2018 Nov 26.

LaRue S, Springer J, Noderer M, Meehan J, Wysham CH. Evaluation of the Use of Exenatide Once-Weekly Suspension Autoinjector Among Patients with Type 2 Diabetes Mellitus and Health Care Professionals. J Diabetes Sci Technol. 2019 Mar;13(2):226-234. doi: 10.1177/1932296818798376. Epub 2018 Sep 20.

Philis-Tsimikas A, Wysham CH, Hardy E, Han J, Iqbal N. Efficacy and tolerability of exenatide once weekly over 7 years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study. J Diabetes Complications. 2019 Mar;33(3):223-230. doi: 10.1016/j.jdiacomp.2018.11.012. Epub 2018 Dec 5.

Bolli GB, Wysham C, Fisher M, Chevalier S, Cali AMG, Leroy B, Riddle MC. A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen. Diabetes Obes Metab. 2019 Feb;21(2):402-407. doi: 10.1111/dom.13515. Epub 2018 Oct 2.

Wysham CH, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Ingham M. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records. J Diabetes Complications. 2019 Feb;33(2):140-147. doi: 10.1016/j.jdiacomp.2018.10.016.

Chaykin L, Bhargava A, de la Rosa R, Wysham CH, Nørgård Troelsen L, Østoft SH,Philis-Tsimikas A. Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial. Clin Diabetes. 2019 Jan;37(1):73-81. doi: 10.2337/cd18-0016.

Miller EM, Wysham CH. Differentiating Among the SGLT-2 Inhibitors: Considering Cardiovascular and Other Safety Outcomes. J Fam Pract. 2018 Aug;67(8 suppl):S37-S42.

Learn more about ongoing studies and medical research at the MultiCare Institute for Research & Innovation.

Return to Search

  • Closest Location

    MultiCare Rockwood Clinic Diabetes & Endocrinology Center

    MultiCare Rockwood Main Clinic
    400 E 5th Ave
    Suite 4 West
    Spokane, WA 99202
    Get Directions

    P. 509-342-3450     F. 509-459-1595

Other Locations
  • MultiCare Rockwood Main Clinic

    400 E Fifth Ave
    Spokane, WA 99202
    Get Directions

    P. 509-838-2531     F. 509-755-6580